» Articles » PMID: 21472497

Improving Power to Detect Disease Progression in Multiple Sclerosis Through Alternative Analysis Strategies

Overview
Journal J Neurol
Specialty Neurology
Date 2011 Apr 8
PMID 21472497
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with multiple sclerosis, investigation of a treatment effect on disease progression in clinical trials and observational studies often uses sustained progression on the expanded disability status scale (EDSS) as an outcome. It is not clear whether this outcome is the most powerful to detect a treatment effect on clinical disease progression. Assessment of EDSS modeling choice on the detection of treatment effect was of interest. This assessment was separately conducted under three potential treatment effects: treatment reducing the chance of higher future EDSS, treatment increasing the chance of lower future EDSS, and treatment leading to both effects. To assess the effect of modeling choice, nine modeling strategies were applied to the data to determine the most powerful approach. EDSS measurements were simulated at 6 month intervals for 24 months. Each patient's initial EDSS value ranged between 0 and 3, and probabilities of transitioning from one EDSS state to another were based on the empirical probabilities of transition obtained from available clinical data. Modeling approaches based on sustained progression had less power than approaches which modeled the EDSS score directly, regardless of treatment effect. This difference was especially pronounced when the treatment effect corresponded to an increase in the probability of improvement. Sustained progression on the EDSS is a less powerful outcome measure for clinical progression than approaches based on the actual EDSS values.

Citing Articles

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.

Healy B, Glanz B, Swallow E, Signorovitch J, Hagan K, Silva D Mult Scler J Exp Transl Clin. 2021; 7(2):2055217321999070.

PMID: 33953937 PMC: 8042549. DOI: 10.1177/2055217321999070.


Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.

Novakovic A, Krekels E, Munafo A, Ueckert S, Karlsson M AAPS J. 2016; 19(1):172-179.

PMID: 27634384 DOI: 10.1208/s12248-016-9977-z.


Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany.

Henze T, von Mackensen S, Lehrieder G, Zettl U, Pfiffner C, Flachenecker P Health Qual Life Outcomes. 2014; 12:119.

PMID: 25080934 PMC: 4148533. DOI: 10.1186/s12955-014-0119-y.


Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Meyer-Moock S, Feng Y, Maeurer M, Dippel F, Kohlmann T BMC Neurol. 2014; 14:58.

PMID: 24666846 PMC: 3986942. DOI: 10.1186/1471-2377-14-58.


A unified framework for the comparison of treatments with ordinal responses.

Lu T, Poon W, Cheung S Psychometrika. 2013; 79(4):605-20.

PMID: 24288031 DOI: 10.1007/s11336-013-9367-8.


References
1.
Zeger S, Liang K . Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. View

2.
Zhao Y, Rahardja D, Qu Y . Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties. Stat Med. 2007; 27(3):462-8. DOI: 10.1002/sim.2912. View

3.
Coles A, Compston D, Selmaj K, Lake S, Moran S, Margolin D . Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359(17):1786-801. DOI: 10.1056/NEJMoa0802670. View

4.
Ebers G, Heigenhauser L, Daumer M, Lederer C, Noseworthy J . Disability as an outcome in MS clinical trials. Neurology. 2008; 71(9):624-31. DOI: 10.1212/01.wnl.0000313034.46883.16. View

5.
Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View